GlassScriptPhysician profile
Zeynep Aydi
NPI 1487881710
$4,391.42
in general payments reported to CMS, 2019-2025
33 companies · $2,085 in 2025
The $2,085 reported for 2025 was more than what 82% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $1,069 · 2022: $33.09 · 2023: $47.97 · 2024: $101 · 2025: $2,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,424 · Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,423.68 |
| Food and Beverage | $810.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $2,070.27 | 2025 | |
| Bioptics, INC. | $508.68 | 2020 | |
| Focal Therapeutics, INC. | $383.06 | 2020 | |
| Novartis Pharmaceuticals Corporation | $126.19 | 2019-2020 | |
| Foundation Medicine, INC. | $124.98 | 2019 | |
| Celgene Corporation | $115.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $107.23 | 2019-2020 | |
| Janssen Biotech, INC. | $98.13 | 2019 | |
| Hologic INC | $90.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.21 | 2019-2020 | |
| Genzyme Corporation | $77.69 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.90 | 2019-2020 | |
| Seagen INC. | $61.59 | 2022-2023 | Adcetris |
| Abbvie INC. | $58.71 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $45.12 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39.93 | 2019-2020 | |
| Daiichi Sankyo INC. | $38.74 | 2019 | |
| Merck Sharp & Dohme LLC | $37.22 | 2019 | |
| Amag Pharmaceuticals, INC. | $30.44 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $21.62 | 2019 | |
| Boston Scientific Corporation | $21.60 | 2024 | |
| Jazz Pharmaceuticals INC. | $20.07 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $20.06 | 2019 | |
| Kci USA, INC. | $19.47 | 2023 | Prevena |
| Sun Pharmaceutical Industries INC. | $17.11 | 2020 | |
| Karyopharm Therapeutics INC. | $15.48 | 2020 | |
| Advanced Oxygen Therapy INC. | $15.12 | 2024 | Topical Oxygen Chamber For Extremities |
| Lilly USA, LLC | $14.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.71 | 2019 | |
| Pfizer INC. | $13.26 | 2019 | |
| Advanced Accelerator Applications | $12.22 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.53 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeynep Aydi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.